Novocure Q2 revenue beats, lifts 2026 outlook

NovoCure

23/07/2026 12:13

    

    Overview
  
Global oncology firm's Q2 revenue rose 16% yr/yr, beating analyst expectations
Company posted Q2 net loss of $15.7 mln
Raised 2026 revenue and adjusted EBITDA guidance on patient growth, product launches

    

    Outlook
  
Novocure raises 2026 revenue guidance to $710 mln-$725 mln from $690 mln-$710 mln
Company expects 2026 adjusted EBITDA of $0 mln-$15 mln, up from prior $(15) mln-$0 mln
Guidance assumes mid-to-high single digit net revenue growth from Optune Gio

    

    Result Drivers
  
ACTIVE PATIENT GROWTH - Q2 revenue increase was primarily driven by 18% global active patient growth across indications
NEW PRODUCT LAUNCHES - Revenue contribution from Optune Pax and Optune Lua, with Optune Pax receiving CE Mark and launching in Germany
ONE-TIME BENEFITS - Q2 revenue included $2.8 mln in one-time benefits in the U.S., Germany and France

    
Company press release: ID:nBw9BdgSJa

    

    Key Details
  

            Metric
          

            Beat/Miss
          

            Actual
          

            Consensus Estimate
          
Q2 Revenue
Beat
$183.58 mln
$172.44 mln (6 Analysts)
Q2 Net Loss
 
$15.66 mln
 
Q2 Gross Profit
 
$142.48 mln
 
Q2 Operating Income
 
-$10.56 mln
 
Q2 Pretax Loss
 
$12.45 mln
 

    

    Analyst Coverage
  
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Novocure Ltd is $23.50, about 50.9% above its July 22 closing price of $15.57

    

    Reuters Recommended Reads
  
July 22 - Medpace Q2 revenue beats estimates on backlog conversion
July 22 - Pfizer's prostate cancer drug combination gets US FDA priority review
July 22 - GSK enters lung cancer drug market with early FDA nod for Jideytro

    
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)